FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3126520172> ?p ?o ?g. }

• W3126520172 endingPage "2623" @default.
• W3126520172 startingPage "2622" @default.
• W3126520172 abstract "We read with great interest the letter by Bangma et al, who corroborated our previous findings, and extended these by demonstrating increased expression of TMPRSS2 in the ileal mucosa of patients with inflammatory bowel disease (IBD) receiving antagonists of tumor necrosis factor α (TNFα). Bangma et al also demonstrate that 5-aminosalicylates (5-ASA) use may be associated with increased colonic TMPRSS2 expression. The translational implications of these emerging data in terms of the prediction of susceptibility and severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in IBD are now key issues, which remain to be established. The observed effect of anti-TNFα therapy on TMPRSS2 expression in Bangma’s report are difficult to reconcile with conclusions from a recent IBD meta-analysis,1Singh A.K. et al.United European Gastroenterol J. 2021; 9: 159-176Crossref PubMed Scopus (70) Google Scholar wherein anti-TNFα agents associated with a 3-fold decrease in the risk of hospitalization for coronavirus disease 2019 (COVID-19). Further investigation is clearly required, focusing both on the gut as well as extraintestinal effects, notably in the respiratory system. For example, can it be that any “negative” effects of TMPRSS2-related facilitation of viral entry in the intestine are more than offset by the effects of TNF blockade in curtailing inflammation in the lungs? This question and related uncertainties in assessing the translational relevance will need to be answered by exploring gene function and expression in parallel with clinical observations, including outcomes from ongoing trials of infliximab in COVID-19 (NCT04425538, NCT04593940). The potential contribution of 5-ASA therapy to the course of COVID-19 is also proving to be complex to unravel. The meta-analysis revealed an increased risk of COVID-19 hospitalization in IBD related to 5-ASA therapy (by 59%).1Singh A.K. et al.United European Gastroenterol J. 2021; 9: 159-176Crossref PubMed Scopus (70) Google Scholar In the SECURE-IBD registry, severe COVID-19 was more frequent in patients receiving 5-ASA (adjusted odds ratio of 1.7).2Ungaro R.C. et al.Gut. 2021; 70: 725-732Crossref PubMed Scopus (187) Google Scholar In discussing the initial SECURE-IBD report,3Brenner E.J. et al.Gastroenterology. 2020; 159: 481-491.e3Abstract Full Text Full Text PDF PubMed Scopus (492) Google Scholar Magro et al pointed out4Magro F. et al.Gastroenterology. 2020; 160: 1884-1885Abstract Full Text Full Text PDF PubMed Scopus (6) Google Scholar that binding of peroxisome proliferator-activated receptor gamma by 5-ASA could induce ACE2 and inhibit TMPRSS2 expression. Here, Bangma et al, to the contrary, indicate increased colonic TMPRSS2 expression in patients with ulcerative colitis receiving aminosalicylates. Again, we suggest that consideration of TMPRSS2 expression in the ileum might not be key for the systemic course of COVID-19. We suggest that it is important to consider the implications and pathogenesis of multiorgan involvement in COVID-19. It is possible that the crucial interaction between 5-ASA and COVID-19 determining outcome does not occur in the intestine, but in the lungs. Mesalazine-induced respiratory disease is unusual, but well-recognised, and may be severe.4Magro F. et al.Gastroenterology. 2020; 160: 1884-1885Abstract Full Text Full Text PDF PubMed Scopus (6) Google Scholar It is interesting to consider the hypothesis that SARS-CoV-2 infection might decrease the threshold for 5-ASA–associated respiratory disease. In susceptible patients, salicylates could augment the production of cysteinyl leukotrienes, thus leading to a stronger inflammatory response. If this hypothesis is valid, then leukotriene antagonists might prove beneficial in patients on 5-ASA with severe COVID-19, or in COVID-19 overall. Hopefully, the trial of montelukast in COVID-19 will provide much-needed answers to this question (NCT04389411). Although ACE2 and TMPRSS2 are known to be main molecules of SARS-CoV-2 entry, other molecular modifiers also are involved; more recently neuropilin-1 (NRP1) was implicated.5Daly J.L. et al.Science. 2020; 370: 861-865Crossref PubMed Scopus (696) Google Scholar Our preliminary re-analysis highlights increased NRP1 expression both in active Crohn’s disease of the ileum and in the mucosa of active ulcerative colitis in data from Vancamelbeke et al.6Vancamelbeke M. et al.Inflamm Bowel Dis. 2017; 23: 1718-1729Crossref PubMed Scopus (100) Google Scholar A greater expression of NRP1 in Crohn’s disease of the ileum compared with ulcerative colitis or controls can be found in data from Haberman et al.7Haberman Y. et al.J Clin Invest. 2014; 124: 3617-3633Crossref PubMed Scopus (342) Google Scholar In ileal biopsies of anti–TNFα-refractory Crohn’s disease patients gathered by Peters et al,8Peters L.A. et al.Nat Genet. 2017; 49: 1437-1449Crossref PubMed Scopus (123) Google Scholar inflamed ileal mucosa had a greater expression of NRP1 relative to uninflamed tissue (P = .002).8Peters L.A. et al.Nat Genet. 2017; 49: 1437-1449Crossref PubMed Scopus (123) Google Scholar Of interest, oncostatin M receptor, which allows oncostatin M to exhibit TNFα-like effects in the presence of anti-TNFα, consistently and strongly correlated with NRP1 in the ileal and colonic mucosa in these 3 datasets (Pearson’s r > 0.7 and P < 10–22). Overall, the evidence for the increased susceptibility to SARS-CoV-2 entry in the inflamed intestine is growing, and our understanding is further strengthened by additional details, such as involvement of specific cell types described by Bangma et al. Defining the relevance of these observations to clinical observation and practice represents an important area for immediate translational research in IBD, and more generally in patients with multisystem COVID-19 illness. The authors thank Dr Jonas Halfvarson and Dr Petr Ricanek for their comments. TNFα-Antagonist Use and Mucosal Inflammation Are Associated with Increased Intestinal Expression of SARS-CoV-2 Host Protease TMPRSS2 in Patients with Inflammatory Bowel DiseaseGastroenterologyVol. 160Issue 7PreviewSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral transfection is dependent on angiotensin-converting enzyme 2 (ACE2) and transmembrane serine protease 2 (TMPRSS2), and increased intestinal receptor expression might support viral replication.1–3 Therefore, we read with great interest the work by Krzysztof et al, reporting that anatomic location, intestinal inflammation, and age are key determinants of intestinal expression of ACE2 and TMPRSS2 in patients with inflammatory bowel disease (IBD). Full-Text PDF" @default.
• W3126520172 created "2021-02-15" @default.
• W3126520172 creator A5013573511 @default.
• W3126520172 creator A5026827841 @default.
• W3126520172 creator A5089781206 @default.
• W3126520172 date "2021-06-01" @default.
• W3126520172 modified "2023-10-16" @default.
• W3126520172 title "Reply" @default.
• W3126520172 cites W2024192805 @default.
• W3126520172 cites W2752299790 @default.
• W3126520172 cites W2753317696 @default.
• W3126520172 cites W3024177957 @default.
• W3126520172 cites W3034621921 @default.
• W3126520172 cites W3094105410 @default.
• W3126520172 cites W3094419073 @default.
• W3126520172 cites W3101694102 @default.
• W3126520172 doi "https://doi.org/10.1053/j.gastro.2021.02.011" @default.
• W3126520172 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33549534" @default.
• W3126520172 hasPublicationYear "2021" @default.
• W3126520172 type Work @default.
• W3126520172 sameAs 3126520172 @default.
• W3126520172 citedByCount "0" @default.
• W3126520172 crossrefType "journal-article" @default.
• W3126520172 hasAuthorship W3126520172A5013573511 @default.
• W3126520172 hasAuthorship W3126520172A5026827841 @default.
• W3126520172 hasAuthorship W3126520172A5089781206 @default.
• W3126520172 hasBestOaLocation W31265201721 @default.
• W3126520172 hasConcept C126322002 @default.
• W3126520172 hasConcept C17991360 @default.
• W3126520172 hasConcept C203014093 @default.
• W3126520172 hasConcept C2777138892 @default.
• W3126520172 hasConcept C2777648638 @default.
• W3126520172 hasConcept C2778042024 @default.
• W3126520172 hasConcept C2778260677 @default.
• W3126520172 hasConcept C2779134260 @default.
• W3126520172 hasConcept C3008058167 @default.
• W3126520172 hasConcept C524204448 @default.
• W3126520172 hasConcept C71924100 @default.
• W3126520172 hasConceptScore W3126520172C126322002 @default.
• W3126520172 hasConceptScore W3126520172C17991360 @default.
• W3126520172 hasConceptScore W3126520172C203014093 @default.
• W3126520172 hasConceptScore W3126520172C2777138892 @default.
• W3126520172 hasConceptScore W3126520172C2777648638 @default.
• W3126520172 hasConceptScore W3126520172C2778042024 @default.
• W3126520172 hasConceptScore W3126520172C2778260677 @default.
• W3126520172 hasConceptScore W3126520172C2779134260 @default.
• W3126520172 hasConceptScore W3126520172C3008058167 @default.
• W3126520172 hasConceptScore W3126520172C524204448 @default.
• W3126520172 hasConceptScore W3126520172C71924100 @default.
• W3126520172 hasFunder F4320338377 @default.
• W3126520172 hasIssue "7" @default.
• W3126520172 hasLocation W31265201721 @default.
• W3126520172 hasLocation W31265201722 @default.
• W3126520172 hasLocation W31265201723 @default.
• W3126520172 hasOpenAccess W3126520172 @default.
• W3126520172 hasPrimaryLocation W31265201721 @default.
• W3126520172 hasRelatedWork W2040595554 @default.
• W3126520172 hasRelatedWork W2060531839 @default.
• W3126520172 hasRelatedWork W2136885623 @default.
• W3126520172 hasRelatedWork W2163972817 @default.
• W3126520172 hasRelatedWork W2273630113 @default.
• W3126520172 hasRelatedWork W2978650559 @default.
• W3126520172 hasRelatedWork W3209514756 @default.
• W3126520172 hasRelatedWork W4225828223 @default.
• W3126520172 hasRelatedWork W4282980674 @default.
• W3126520172 hasRelatedWork W2074509533 @default.
• W3126520172 hasVolume "160" @default.
• W3126520172 isParatext "false" @default.
• W3126520172 isRetracted "false" @default.
• W3126520172 magId "3126520172" @default.
• W3126520172 workType "article" @default.